Keryx Biopharmaceuticals Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Keryx Biopharmaceuticals Inc |
Stock Symbol : | NASDAQ: KERX |
Class Period Start: | 02/25/2016 |
Class Period End: | 08/01/2016 |
Lead Plaintiff motion: | 10/03/2016 |
Date Filed: | 08/02/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the October 3, 2016 lead plaintiff deadline in a class action lawsuit filed against Keryx Biopharmaceuticals Inc (NASDAQ: KERX) (“Keryx” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Keryx Biopharmaceuticals Inc securities between February 25, 2016 and August 1, 2016, have until October 3, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Keryx Biopharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that, as a result, the Company would, and did exhaust its reserve of finished drug product; and as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. On August 1, 2016, Keryx revealed that patients who use Keryx's kidney drug Auryxia will face a supply interruption until at least October due to a "production-related issue." Following this news, the Company's stock price fell $2.64 per share, or 35.8%, to close at $4.72 per share on August 1, 2016. If you were negatively impacted by your investment in Keryx Biopharmaceuticals Inc securities between February 25, 2016 and August 1, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185
|